Pluripotent stem cells (PSCs) offer an unlimited source of human cardiovascular cells for research and the development of cardiac regeneration therapies. The development of highly efficient ...

The ability to derive induced pluripotent stem cells (iPSCs) from differentiated cell types such as fibroblasts, has revolutionized drug discovery for many disease areas including neurodegenerative ...

Stem cell research is a rapidly growing field of study with huge potential for clinical solutions, taking advantage of the power and flexibility of pluripotency and self-renewal. Induced pluripotent ...

TFome™, the world’s first “plug-and-play” iPSC cellular programming platform, streamlines development and accelerates pipeline of potential best-in-class cell therapies across diverse therapeutic ...

Nicola Bevan is a manager in the BioAnalytics Applications Group (Royston, UK) of Sartorius (Göttingen, Germany). Her team is focused on the development of novel applications and delivering ...

The progress in induced pluripotent stem cells (iPSCs) and organoid technology has addressed the lack of suitable in vitro models for human neurodevelopmental and degenerative disorders. Over the past ...

The research in our laboratory is focused, among others, on developmental biology, with a particular emphasis on the differentiation of dental epithelial and mesenchymal progenitors and the ...

Researchers across discovery and translational biomedicine recognize the critical importance of iPSCs in core applications beyond regenerative medicine. Large, global biobanks offer researchers ...

Cellular immunotherapy—for example, Chimeric Antigen Receptor (CAR)-T cell therapy—has shown great efficacy in treating various hematologic malignancies. CAR-T therapy has undergone notable changes, ...